News
Asianet Newsable on MSN59m
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay OptimisticThe median progression-free survival was 32.6 months on the Blenrep combo compared to 12.5 months on the alternative. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback